StreetInsider.com News Articles

Lifecore Biomedical signs ophthalmic manufacturing agreement

Tue, 02 Jun 2026 07:05:19 -0400

Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced it has signed a manufacturing services agreement with an ophthalmic disease management company for process development and technical transfer services.

The Chaska, Minnesota-based contract development and manufacturing organization will support the transition of a commercially approved ophthalmic product from vials to pre-filled syringes. The work is intended to prepare for potential commercial manufacturing pending regulatory approval.

"We are pleased to announce another customer win and the opportunity to support an important new technical transfer program," said Paul Josephs, chief executive officer of Lifecore. "This agreement reflects Lifecore's recognized, technical expertise and specialized manufacturing capabilities in the

Lifecore Biomedical signs ophthalmic manufacturing agreement

Tue, 02 Jun 2026 07:05:19 -0400

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Tue, 02 Jun 2026 07:05:00 -0400

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product --

-- Sixth Addition to Late-Stage Pipeline in Seven Months --

CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform process development and technical transfer services in support of anticipated commercial manufacturing upon regulatory

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Tue, 02 Jun 2026 07:05:00 -0400

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product --

-- Sixth Addition to Late-Stage Pipeline in Seven Months --

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Tue, 02 Jun 2026 07:05:00 -0400

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product --

-- Sixth Addition to Late-Stage Pipeline in Seven Months --

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Tue, 02 Jun 2026 07:05:00 -0400

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product --

-- Sixth Addition to Late-Stage Pipeline in Seven Months --

Form 4 LIFECORE BIOMEDICAL, For: May 20 Filed by: Josephs Paul

Thu, 21 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260521/26535852.html

Form 4 LIFECORE BIOMEDICAL, For: May 20 Filed by: Josephs Paul

Thu, 21 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260521/26535852.html

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

Thu, 21 May 2026 07:05:00 -0400

CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the William Blair 46th Annual Growth Stock Conference. The conference will take place June 2-4, 2026, in Chicago, IL.